Track topics on Twitter Track topics that are important to you
The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask t...
At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer t...
In the FALCON trial, fulvestrant improved PFS in ER+ metastatic breast cancer patients who were endocrine-therapy naive, but the trial failed to answer key clinical questions, says Dr Lidia Schapira. ...
(Provista Diagnostics) Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results & potentially reduce biopsies up to 67%.
(Provista Diagnostics) A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analyzing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherap...
Merrimack Pharmaceuticals has stopped a phase 2 trial of its breast cancer treatment after an analysis suggested the drug would unlikely show benefit over the comparator treatments.
Scope of the ReportThe report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer 20162020, provides analysis of the global cancer diagnostics market and the US cancer diagno...
In black patients with breast cancer, what type of treatment attenuated aggressive recurrent rates? What percentage of women with early-stage invasive breast cancer report at least one severe/very sev...
BriaCell Therapeutics Corp. has submitted a chemistry, manufacturing and control (CMC) amendment to the US FDA before its planned stem-cell based vaccine trial for late stage breast cancer.
Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following breast-conserving therapy.
SUPREMO is a phase 3 randomised trial evaluating radiotherapy post-mastectomy for intermediate-risk breast cancer. 1688 patients were enrolled from 16 countries between 2006 and 2013. We report the re...
Breast-conserving surgery (BCS) followed by radiotherapy (RT) is an established treatment for women with T1-2N0 breast cancers. Since subgroups of patients have low ipsilateral breast tumour recurrenc...
We aim to assess any association between study and self-reported conflict of interest (COI) or trial sponsorship in breast cancer radiation clinical trials.
This study examines the accuracy of the Test of Memory Malingering (TOMM), a frequently administered measure for evaluating effort during neurocognitive testing. In the last few years, several authors...